^
    11d
    Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (clinicaltrials.gov)
    P4, N=268, Not yet recruiting, SWOG Cancer Research Network
    New P4 trial
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    11d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)
    22d
    A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2027 --> Apr 2028
    Trial completion date • First-in-human • CALR
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    2ms
    Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, United Lincolnshire Hospitals NHS Trust
    New P2 trial
    |
    Ojjaara (momelotinib) • bomedemstat (MK-3543)
    2ms
    GFM-VEXAS-MMB: Momelotinib in VEXAS syndrome (2024-519779-24-00)
    P1/2, N=57, Recruiting, Groupe Francophone Des Myelodysplasies
    New P1/2 trial
    |
    Ojjaara (momelotinib)
    2ms
    SENTRY-2: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (clinicaltrials.gov)
    P2, N=58, Recruiting, Karyopharm Therapeutics Inc | N=118 --> 58 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial primary completion date
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor) • Vonjo (pacritinib) • Ojjaara (momelotinib)
    2ms
    Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)
    P1, N=28, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    Ojjaara (momelotinib)
    2ms
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial primary completion date
    |
    azacitidine • Ojjaara (momelotinib)
    3ms
    Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity. (PubMed, Otol Neurotol)
    JAK1 and JAK2 inhibition worsens cochlear damage in mice exposed to aminoglycosides.
    Journal
    |
    JAK1 (Janus Kinase 1) • CDH2 (Cadherin 2) • CDH3 (Cadherin 3) • CDH23 (Cadherin Related 23)
    |
    Ojjaara (momelotinib)
    4ms
    Current treatments, practical management, and emerging investigational therapies for myelofibrosis. (PubMed, Expert Rev Hematol)
    Equally, there is a major focus on next generation JAK inhibitors and mutant calreticulin antibodies. There is also increasing conversation around the need for novel endpoints, as the limitations of symptom assessment, in particular, become apparent and candidate biomarkers of disease modification emerge.
    Review • Journal
    |
    CALR (Calreticulin)
    |
    CALR mutation
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    4ms
    IKBKE modulates autophagy and progestin resistance in endometrial cancer. (PubMed, Front Oncol)
    A progestin-resistant EC cell line was established to assess the effects of IKBKE knockdown and treatment with CYT387, a selective IKBKE inhibitor...These findings highlight the crucial role of IKBKE in regulating autophagy and mediating progestin resistance in EC. This study provides new insights into IKBKE as a potential molecular target that contributes to understanding the mechanisms underlying progestin resistance in endometrial cancer.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    Ojjaara (momelotinib)
    4ms
    Momelotinib in VEXAS Syndrome (clinicaltrials.gov)
    P2, N=57, Recruiting, Groupe Francophone des Myelodysplasies | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ojjaara (momelotinib)